<?xml version="1.0"?>
<rss version="2.0">
 <channel>
  <title>StreetInsider.com News Articles</title>
  <link>http://new.streetinsider.com</link>
  <description>Latest StreetInsider.com News Articles</description>
  <language>en-us</language>
  <copyright>Copyright 2026, StreetInsider.com</copyright>
  <managingEditor>rss@streetinsider.com (SI RSS)</managingEditor>
  <webMaster>rss@streetinsider.com (SI RSS)</webMaster>
  <lastBuildDate>Mon, 21 Sep 2026 03:49:21 -0400</lastBuildDate>
  <docs>http://blogs.law.harvard.edu/tech/rss</docs>
  <image>
   <url>http://www.streetinsider.com/images/rss_logo.gif</url>
   <title>StreetInsider.com News Articles</title>
   <link>http://new.streetinsider.com</link>
   <width>143</width>
   <height>28</height>
  </image>
  <skipHours>
   <hour>0</hour>
   <hour>1</hour>
   <hour>2</hour>
   <hour>3</hour>
   <hour>21</hour>
   <hour>22</hour>
   <hour>23</hour>
  </skipHours>
  <skipDays>
   <day>Saturday</day>
   <day>Sunday</day>
  </skipDays>
  <item>
   <title>UBS Upgrades H Lundbeck A/S (HLUNB:DC) (HLUYY) to Buy</title>
   <link>http://www.streetinsider.com/Intl+Ratings/UBS+Upgrades+H+Lundbeck+AS+%28HLUNB%3ADC%29+%28HLUYY%29+to+Buy/27082186.html</link>
   <description>&lt;p&gt;UBS analyst Xian Deng upgraded H Lundbeck A/S (HLUNB:DC) (OTC: HLUYY) from Neutral to Buy with a price target of DKK52.00 (from DKK45.00).&lt;/p&gt;&lt;p&gt;The analyst comments: “R&amp;D turnaround is one of the hardest challenges in the pharma industry. Only a few companies have successfully done it, and we think Lundbeck could be one of them. Lundbeck has been trading at ~50% discount to sector average, due to its legacy in psychiatry, where R&amp;D has high failure rates. To make its story even harder, Lundbeck faces a significant patent cliff when the Rexulti patent expires in 2029. These may be about to</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Intl+Ratings/UBS+Upgrades+H+Lundbeck+AS+%28HLUNB%3ADC%29+%28HLUYY%29+to+Buy/27082186.html</guid>
   <pubDate>Mon, 21 Sep 2026 03:49:21 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">HLUYY</category>
   	  </item>
  <item>
   <title>UBS Upgrades H Lundbeck A/S (HLUNB:DC) (HLUYY) to Buy</title>
   <link>http://www.streetinsider.com/Upgrades/UBS+Upgrades+H+Lundbeck+AS+%28HLUNB%3ADC%29+%28HLUYY%29+to+Buy/27082186.html</link>
   <description>&lt;p&gt;UBS analyst Xian Deng upgraded H Lundbeck A/S (HLUNB:DC) (OTC: HLUYY) from Neutral to Buy with a price target of DKK52.00 (from DKK45.00).&lt;/p&gt;&lt;p&gt;The analyst comments: “R&amp;D turnaround is one of the hardest challenges in the pharma industry. Only a few companies have successfully done it, and we think Lundbeck could be one of them. Lundbeck has been trading at ~50% discount to sector average, due to its legacy in psychiatry, where R&amp;D has high failure rates. To make its story even harder, Lundbeck faces a significant patent cliff when the Rexulti patent expires in 2029. These may be about to</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Upgrades/UBS+Upgrades+H+Lundbeck+AS+%28HLUNB%3ADC%29+%28HLUYY%29+to+Buy/27082186.html</guid>
   <pubDate>Mon, 21 Sep 2026 03:49:21 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">HLUYY</category>
   	  </item>
  <item>
   <title>UBS Upgrades H Lundbeck A/S (HLUNB:DC) (HLUYY) to Buy</title>
   <link>http://www.streetinsider.com/Analyst+Comments/UBS+Upgrades+H+Lundbeck+AS+%28HLUNB%3ADC%29+%28HLUYY%29+to+Buy/27082186.html</link>
   <description>&lt;p&gt;UBS analyst Xian Deng upgraded H Lundbeck A/S (HLUNB:DC) (OTC: HLUYY) from Neutral to Buy with a price target of DKK52.00 (from DKK45.00).&lt;/p&gt;&lt;p&gt;The analyst comments: “R&amp;D turnaround is one of the hardest challenges in the pharma industry. Only a few companies have successfully done it, and we think Lundbeck could be one of them. Lundbeck has been trading at ~50% discount to sector average, due to its legacy in psychiatry, where R&amp;D has high failure rates. To make its story even harder, Lundbeck faces a significant patent cliff when the Rexulti patent expires in 2029. These may be about to</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Analyst+Comments/UBS+Upgrades+H+Lundbeck+AS+%28HLUNB%3ADC%29+%28HLUYY%29+to+Buy/27082186.html</guid>
   <pubDate>Mon, 21 Sep 2026 03:49:21 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">HLUYY</category>
   	  </item>
  <item>
   <title>UBS Upgrades H Lundbeck A/S (HLUNB:DC) (HLUYY) to Buy</title>
   <link>http://www.streetinsider.com/Intl+Ratings/UBS+Upgrades+H+Lundbeck+AS+%28HLUNB%3ADC%29+%28HLUYY%29+to+Buy/27082186.html</link>
   <description>&lt;p&gt;UBS analyst Xian Deng upgraded H Lundbeck A/S (HLUNB:DC) (OTC: HLUYY) from Neutral to Buy with a price target of DKK52.00 (from DKK45.00).&lt;/p&gt;&lt;p&gt;The analyst comments: “R&amp;D turnaround is one of the hardest challenges in the pharma industry. Only a few companies have successfully done it, and we think Lundbeck could be one of them. Lundbeck has been trading at ~50% discount to sector average, due to its legacy in psychiatry, where R&amp;D has high failure rates. To make its story even harder, Lundbeck faces a significant patent cliff when the Rexulti patent expires in 2029. These may be about to</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Intl+Ratings/UBS+Upgrades+H+Lundbeck+AS+%28HLUNB%3ADC%29+%28HLUYY%29+to+Buy/27082186.html</guid>
   <pubDate>Mon, 21 Sep 2026 03:49:21 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">HLUYY</category>
   	  </item>
  <item>
   <title>UBS Upgrades H Lundbeck A/S (HLUNB:DC) (HLUYY) to Buy</title>
   <link>http://www.streetinsider.com/Upgrades/UBS+Upgrades+H+Lundbeck+AS+%28HLUNB%3ADC%29+%28HLUYY%29+to+Buy/27082186.html</link>
   <description>&lt;p&gt;UBS analyst Xian Deng upgraded H Lundbeck A/S (HLUNB:DC) (OTC: HLUYY) from Neutral to Buy with a price target of DKK52.00 (from DKK45.00).&lt;/p&gt;&lt;p&gt;The analyst comments: “R&amp;D turnaround is one of the hardest challenges in the pharma industry. Only a few companies have successfully done it, and we think Lundbeck could be one of them. Lundbeck has been trading at ~50% discount to sector average, due to its legacy in psychiatry, where R&amp;D has high failure rates. To make its story even harder, Lundbeck faces a significant patent cliff when the Rexulti patent expires in 2029. These may be about to</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Upgrades/UBS+Upgrades+H+Lundbeck+AS+%28HLUNB%3ADC%29+%28HLUYY%29+to+Buy/27082186.html</guid>
   <pubDate>Mon, 21 Sep 2026 03:49:21 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">HLUYY</category>
   	  </item>
  <item>
   <title>UBS Upgrades H Lundbeck A/S (HLUNB:DC) (HLUYY) to Buy</title>
   <link>http://www.streetinsider.com/Analyst+Comments/UBS+Upgrades+H+Lundbeck+AS+%28HLUNB%3ADC%29+%28HLUYY%29+to+Buy/27082186.html</link>
   <description>&lt;p&gt;UBS analyst Xian Deng upgraded H Lundbeck A/S (HLUNB:DC) (OTC: HLUYY) from Neutral to Buy with a price target of DKK52.00 (from DKK45.00).&lt;/p&gt;&lt;p&gt;The analyst comments: “R&amp;D turnaround is one of the hardest challenges in the pharma industry. Only a few companies have successfully done it, and we think Lundbeck could be one of them. Lundbeck has been trading at ~50% discount to sector average, due to its legacy in psychiatry, where R&amp;D has high failure rates. To make its story even harder, Lundbeck faces a significant patent cliff when the Rexulti patent expires in 2029. These may be about to</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Analyst+Comments/UBS+Upgrades+H+Lundbeck+AS+%28HLUNB%3ADC%29+%28HLUYY%29+to+Buy/27082186.html</guid>
   <pubDate>Mon, 21 Sep 2026 03:49:21 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">HLUYY</category>
   	  </item>
  <item>
   <title>Deutsche Bank Downgrades H Lundbeck A/S (HLUNB:DC) (HLUYY) to Sell</title>
   <link>http://www.streetinsider.com/Intl+Ratings/Deutsche+Bank+Downgrades+H+Lundbeck+AS+%28HLUNB%3ADC%29+%28HLUYY%29+to+Sell/27060079.html</link>
   <description>&lt;p&gt;Deutsche Bank analyst Niall Alexander downgraded H Lundbeck A/S (HLUNB:DC) (OTC: HLUYY) from Hold to Sell with a price target of DKK36.00 (from DKK40.00).&lt;/p&gt;&lt;p&gt;The analyst comments: “With LUN's upcoming P3 DEEp OCEAN readout due in Q4, assessing acquired Longboard asset bexicaserin in LGS/DS/DEE epilepsy, we take the opportunity to revisit the epilepsy space alongside emerging late stage pipeline assets. We've highlighted in previous publications our cautious view on the stock given headwinds for Rexulti (asset currently makes up ~25% of total revenue) including competitor Auvelity, it's listing in 2028 IRA price cut (Rexulti US sales ~35% Medicare) and patent cliff</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Intl+Ratings/Deutsche+Bank+Downgrades+H+Lundbeck+AS+%28HLUNB%3ADC%29+%28HLUYY%29+to+Sell/27060079.html</guid>
   <pubDate>Tue, 15 Sep 2026 03:20:33 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">HLUYY</category>
   	  </item>
  <item>
   <title>Deutsche Bank Downgrades H Lundbeck A/S (HLUNB:DC) (HLUYY) to Sell</title>
   <link>http://www.streetinsider.com/Downgrades/Deutsche+Bank+Downgrades+H+Lundbeck+AS+%28HLUNB%3ADC%29+%28HLUYY%29+to+Sell/27060079.html</link>
   <description>&lt;p&gt;Deutsche Bank analyst Niall Alexander downgraded H Lundbeck A/S (HLUNB:DC) (OTC: HLUYY) from Hold to Sell with a price target of DKK36.00 (from DKK40.00).&lt;/p&gt;&lt;p&gt;The analyst comments: “With LUN's upcoming P3 DEEp OCEAN readout due in Q4, assessing acquired Longboard asset bexicaserin in LGS/DS/DEE epilepsy, we take the opportunity to revisit the epilepsy space alongside emerging late stage pipeline assets. We've highlighted in previous publications our cautious view on the stock given headwinds for Rexulti (asset currently makes up ~25% of total revenue) including competitor Auvelity, it's listing in 2028 IRA price cut (Rexulti US sales ~35% Medicare) and patent cliff</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Downgrades/Deutsche+Bank+Downgrades+H+Lundbeck+AS+%28HLUNB%3ADC%29+%28HLUYY%29+to+Sell/27060079.html</guid>
   <pubDate>Tue, 15 Sep 2026 03:20:33 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">HLUYY</category>
   	  </item>
  <item>
   <title>Deutsche Bank Downgrades H Lundbeck A/S (HLUNB:DC) (HLUYY) to Sell</title>
   <link>http://www.streetinsider.com/Analyst+Comments/Deutsche+Bank+Downgrades+H+Lundbeck+AS+%28HLUNB%3ADC%29+%28HLUYY%29+to+Sell/27060079.html</link>
   <description>&lt;p&gt;Deutsche Bank analyst Niall Alexander downgraded H Lundbeck A/S (HLUNB:DC) (OTC: HLUYY) from Hold to Sell with a price target of DKK36.00 (from DKK40.00).&lt;/p&gt;&lt;p&gt;The analyst comments: “With LUN's upcoming P3 DEEp OCEAN readout due in Q4, assessing acquired Longboard asset bexicaserin in LGS/DS/DEE epilepsy, we take the opportunity to revisit the epilepsy space alongside emerging late stage pipeline assets. We've highlighted in previous publications our cautious view on the stock given headwinds for Rexulti (asset currently makes up ~25% of total revenue) including competitor Auvelity, it's listing in 2028 IRA price cut (Rexulti US sales ~35% Medicare) and patent cliff</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Analyst+Comments/Deutsche+Bank+Downgrades+H+Lundbeck+AS+%28HLUNB%3ADC%29+%28HLUYY%29+to+Sell/27060079.html</guid>
   <pubDate>Tue, 15 Sep 2026 03:20:33 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">HLUYY</category>
   	  </item>
  <item>
   <title>Deutsche Bank Downgrades H Lundbeck A/S (HLUNB:DC) (HLUYY) to Sell</title>
   <link>http://www.streetinsider.com/Intl+Ratings/Deutsche+Bank+Downgrades+H+Lundbeck+AS+%28HLUNB%3ADC%29+%28HLUYY%29+to+Sell/27060079.html</link>
   <description>&lt;p&gt;Deutsche Bank analyst Niall Alexander downgraded H Lundbeck A/S (HLUNB:DC) (OTC: HLUYY) from Hold to Sell with a price target of DKK36.00 (from DKK40.00).&lt;/p&gt;&lt;p&gt;The analyst comments: “With LUN's upcoming P3 DEEp OCEAN readout due in Q4, assessing acquired Longboard asset bexicaserin in LGS/DS/DEE epilepsy, we take the opportunity to revisit the epilepsy space alongside emerging late stage pipeline assets. We've highlighted in previous publications our cautious view on the stock given headwinds for Rexulti (asset currently makes up ~25% of total revenue) including competitor Auvelity, it's listing in 2028 IRA price cut (Rexulti US sales ~35% Medicare) and patent cliff</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Intl+Ratings/Deutsche+Bank+Downgrades+H+Lundbeck+AS+%28HLUNB%3ADC%29+%28HLUYY%29+to+Sell/27060079.html</guid>
   <pubDate>Tue, 15 Sep 2026 03:20:33 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">HLUYY</category>
   	  </item>
  <item>
   <title>Deutsche Bank Downgrades H Lundbeck A/S (HLUNB:DC) (HLUYY) to Sell</title>
   <link>http://www.streetinsider.com/Downgrades/Deutsche+Bank+Downgrades+H+Lundbeck+AS+%28HLUNB%3ADC%29+%28HLUYY%29+to+Sell/27060079.html</link>
   <description>&lt;p&gt;Deutsche Bank analyst Niall Alexander downgraded H Lundbeck A/S (HLUNB:DC) (OTC: HLUYY) from Hold to Sell with a price target of DKK36.00 (from DKK40.00).&lt;/p&gt;&lt;p&gt;The analyst comments: “With LUN's upcoming P3 DEEp OCEAN readout due in Q4, assessing acquired Longboard asset bexicaserin in LGS/DS/DEE epilepsy, we take the opportunity to revisit the epilepsy space alongside emerging late stage pipeline assets. We've highlighted in previous publications our cautious view on the stock given headwinds for Rexulti (asset currently makes up ~25% of total revenue) including competitor Auvelity, it's listing in 2028 IRA price cut (Rexulti US sales ~35% Medicare) and patent cliff</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Downgrades/Deutsche+Bank+Downgrades+H+Lundbeck+AS+%28HLUNB%3ADC%29+%28HLUYY%29+to+Sell/27060079.html</guid>
   <pubDate>Tue, 15 Sep 2026 03:20:33 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">HLUYY</category>
   	  </item>
  <item>
   <title>Deutsche Bank Downgrades H Lundbeck A/S (HLUNB:DC) (HLUYY) to Sell</title>
   <link>http://www.streetinsider.com/Analyst+Comments/Deutsche+Bank+Downgrades+H+Lundbeck+AS+%28HLUNB%3ADC%29+%28HLUYY%29+to+Sell/27060079.html</link>
   <description>&lt;p&gt;Deutsche Bank analyst Niall Alexander downgraded H Lundbeck A/S (HLUNB:DC) (OTC: HLUYY) from Hold to Sell with a price target of DKK36.00 (from DKK40.00).&lt;/p&gt;&lt;p&gt;The analyst comments: “With LUN's upcoming P3 DEEp OCEAN readout due in Q4, assessing acquired Longboard asset bexicaserin in LGS/DS/DEE epilepsy, we take the opportunity to revisit the epilepsy space alongside emerging late stage pipeline assets. We've highlighted in previous publications our cautious view on the stock given headwinds for Rexulti (asset currently makes up ~25% of total revenue) including competitor Auvelity, it's listing in 2028 IRA price cut (Rexulti US sales ~35% Medicare) and patent cliff</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Analyst+Comments/Deutsche+Bank+Downgrades+H+Lundbeck+AS+%28HLUNB%3ADC%29+%28HLUYY%29+to+Sell/27060079.html</guid>
   <pubDate>Tue, 15 Sep 2026 03:20:33 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">HLUYY</category>
   	  </item>
  <item>
   <title>H Lundbeck A/S (LUN:DC) (HLUYY) PT Raised to DKK50 at Barclays</title>
   <link>http://www.streetinsider.com/Intl+Ratings/H+Lundbeck+AS+%28LUN%3ADC%29+%28HLUYY%29+PT+Raised+to+DKK50+at+Barclays/27032443.html</link>
   <description>Barclays analyst Rosie Turner raised the price target on H Lundbeck A/S (LUN:DC) (OTC: HLUYY) to DKK50.00  (from DKK48.00) while maintaining a Equalweight rating.</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Intl+Ratings/H+Lundbeck+AS+%28LUN%3ADC%29+%28HLUYY%29+PT+Raised+to+DKK50+at+Barclays/27032443.html</guid>
   <pubDate>Tue, 08 Sep 2026 05:38:42 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">HLUYY</category>
   	  </item>
  <item>
   <title>H Lundbeck A/S (LUN:DC) (HLUYY) PT Raised to DKK50 at Barclays</title>
   <link>http://www.streetinsider.com/Analyst+PT+Change/H+Lundbeck+AS+%28LUN%3ADC%29+%28HLUYY%29+PT+Raised+to+DKK50+at+Barclays/27032443.html</link>
   <description>Barclays analyst Rosie Turner raised the price target on H Lundbeck A/S (LUN:DC) (OTC: HLUYY) to DKK50.00  (from DKK48.00) while maintaining a Equalweight rating.</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Analyst+PT+Change/H+Lundbeck+AS+%28LUN%3ADC%29+%28HLUYY%29+PT+Raised+to+DKK50+at+Barclays/27032443.html</guid>
   <pubDate>Tue, 08 Sep 2026 05:38:42 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">HLUYY</category>
   	  </item>
  <item>
   <title>H Lundbeck A/S (LUN:DC) (HLUYY) PT Raised to DKK50 at Barclays</title>
   <link>http://www.streetinsider.com/Intl+Ratings/H+Lundbeck+AS+%28LUN%3ADC%29+%28HLUYY%29+PT+Raised+to+DKK50+at+Barclays/27032443.html</link>
   <description>Barclays analyst Rosie Turner raised the price target on H Lundbeck A/S (LUN:DC) (OTC: HLUYY) to DKK50.00  (from DKK48.00) while maintaining a Equalweight rating.</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Intl+Ratings/H+Lundbeck+AS+%28LUN%3ADC%29+%28HLUYY%29+PT+Raised+to+DKK50+at+Barclays/27032443.html</guid>
   <pubDate>Tue, 08 Sep 2026 05:38:42 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">HLUYY</category>
   	  </item>
  <item>
   <title>H Lundbeck A/S (LUN:DC) (HLUYY) PT Raised to DKK50 at Barclays</title>
   <link>http://www.streetinsider.com/Analyst+PT+Change/H+Lundbeck+AS+%28LUN%3ADC%29+%28HLUYY%29+PT+Raised+to+DKK50+at+Barclays/27032443.html</link>
   <description>Barclays analyst Rosie Turner raised the price target on H Lundbeck A/S (LUN:DC) (OTC: HLUYY) to DKK50.00  (from DKK48.00) while maintaining a Equalweight rating.</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Analyst+PT+Change/H+Lundbeck+AS+%28LUN%3ADC%29+%28HLUYY%29+PT+Raised+to+DKK50+at+Barclays/27032443.html</guid>
   <pubDate>Tue, 08 Sep 2026 05:38:42 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">HLUYY</category>
   	  </item>
  <item>
   <title>BofA Securities Reiterates Underperform Rating on H Lundbeck A/S (LUN:DC) (HLUYY)</title>
   <link>http://www.streetinsider.com/Intl+Ratings/BofA+Securities+Reiterates+Underperform+Rating+on+H+Lundbeck+AS+%28LUN%3ADC%29+%28HLUYY%29/27027364.html</link>
   <description>&lt;p&gt;BofA Securities reiterated an Underperform rating and DKK34.00 price target on H Lundbeck A/S (LUN:DC) (OTC: HLUYY).&lt;/p&gt;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Intl+Ratings/BofA+Securities+Reiterates+Underperform+Rating+on+H+Lundbeck+AS+%28LUN%3ADC%29+%28HLUYY%29/27027364.html</guid>
   <pubDate>Fri, 04 Sep 2026 06:07:56 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">HLUYY</category>
   	  </item>
  <item>
   <title>BofA Securities Reiterates Underperform Rating on H Lundbeck A/S (LUN:DC) (HLUYY)</title>
   <link>http://www.streetinsider.com/Intl+Ratings/BofA+Securities+Reiterates+Underperform+Rating+on+H+Lundbeck+AS+%28LUN%3ADC%29+%28HLUYY%29/27027364.html</link>
   <description>&lt;p&gt;BofA Securities reiterated an Underperform rating and DKK34.00 price target on H Lundbeck A/S (LUN:DC) (OTC: HLUYY).&lt;/p&gt;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Intl+Ratings/BofA+Securities+Reiterates+Underperform+Rating+on+H+Lundbeck+AS+%28LUN%3ADC%29+%28HLUYY%29/27027364.html</guid>
   <pubDate>Fri, 04 Sep 2026 06:07:56 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">HLUYY</category>
   	  </item>
  <item>
   <title>H Lundbeck A/S (HLUNB:DC) (HLUYY) PT Raised to DKK45 at UBS</title>
   <link>http://www.streetinsider.com/Intl+Ratings/H+Lundbeck+AS+%28HLUNB%3ADC%29+%28HLUYY%29+PT+Raised+to+DKK45+at+UBS/26952732.html</link>
   <description>UBS analyst Xian Deng raised the price target on H Lundbeck A/S (HLUNB:DC) (OTC: HLUYY) to DKK45.00  (from DKK44.00) while maintaining a Neutral rating.</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Intl+Ratings/H+Lundbeck+AS+%28HLUNB%3ADC%29+%28HLUYY%29+PT+Raised+to+DKK45+at+UBS/26952732.html</guid>
   <pubDate>Thu, 20 Aug 2026 07:13:15 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">HLUYY</category>
   	  </item>
  <item>
   <title>H Lundbeck A/S (HLUNB:DC) (HLUYY) PT Raised to DKK45 at UBS</title>
   <link>http://www.streetinsider.com/Analyst+PT+Change/H+Lundbeck+AS+%28HLUNB%3ADC%29+%28HLUYY%29+PT+Raised+to+DKK45+at+UBS/26952732.html</link>
   <description>UBS analyst Xian Deng raised the price target on H Lundbeck A/S (HLUNB:DC) (OTC: HLUYY) to DKK45.00  (from DKK44.00) while maintaining a Neutral rating.</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Analyst+PT+Change/H+Lundbeck+AS+%28HLUNB%3ADC%29+%28HLUYY%29+PT+Raised+to+DKK45+at+UBS/26952732.html</guid>
   <pubDate>Thu, 20 Aug 2026 07:13:15 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">HLUYY</category>
   	  </item>
  <item>
   <title>H Lundbeck A/S (HLUNB:DC) (HLUYY) PT Raised to DKK45 at UBS</title>
   <link>http://www.streetinsider.com/Intl+Ratings/H+Lundbeck+AS+%28HLUNB%3ADC%29+%28HLUYY%29+PT+Raised+to+DKK45+at+UBS/26952732.html</link>
   <description>UBS analyst Xian Deng raised the price target on H Lundbeck A/S (HLUNB:DC) (OTC: HLUYY) to DKK45.00  (from DKK44.00) while maintaining a Neutral rating.</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Intl+Ratings/H+Lundbeck+AS+%28HLUNB%3ADC%29+%28HLUYY%29+PT+Raised+to+DKK45+at+UBS/26952732.html</guid>
   <pubDate>Thu, 20 Aug 2026 07:13:15 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">HLUYY</category>
   	  </item>
  <item>
   <title>H Lundbeck A/S (HLUNB:DC) (HLUYY) PT Raised to DKK45 at UBS</title>
   <link>http://www.streetinsider.com/Analyst+PT+Change/H+Lundbeck+AS+%28HLUNB%3ADC%29+%28HLUYY%29+PT+Raised+to+DKK45+at+UBS/26952732.html</link>
   <description>UBS analyst Xian Deng raised the price target on H Lundbeck A/S (HLUNB:DC) (OTC: HLUYY) to DKK45.00  (from DKK44.00) while maintaining a Neutral rating.</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Analyst+PT+Change/H+Lundbeck+AS+%28HLUNB%3ADC%29+%28HLUYY%29+PT+Raised+to+DKK45+at+UBS/26952732.html</guid>
   <pubDate>Thu, 20 Aug 2026 07:13:15 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">HLUYY</category>
   	  </item>
  <item>
   <title>H Lundbeck A/S (HLUNB:DC) (HLUYY) PT Raised to DKK48 at Barclays</title>
   <link>http://www.streetinsider.com/Intl+Ratings/H+Lundbeck+AS+%28HLUNB%3ADC%29+%28HLUYY%29+PT+Raised+to+DKK48+at+Barclays/26781242.html</link>
   <description>Barclays analyst Charles Pitman raised the price target on H Lundbeck A/S (HLUNB:DC) (OTC: HLUYY) to DKK48.00  (from DKK45.00) while maintaining a Equalweight rating.</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Intl+Ratings/H+Lundbeck+AS+%28HLUNB%3ADC%29+%28HLUYY%29+PT+Raised+to+DKK48+at+Barclays/26781242.html</guid>
   <pubDate>Fri, 17 Jul 2026 04:49:05 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">HLUYY</category>
   	  </item>
  <item>
   <title>H Lundbeck A/S (HLUNB:DC) (HLUYY) PT Raised to DKK48 at Barclays</title>
   <link>http://www.streetinsider.com/Analyst+PT+Change/H+Lundbeck+AS+%28HLUNB%3ADC%29+%28HLUYY%29+PT+Raised+to+DKK48+at+Barclays/26781242.html</link>
   <description>Barclays analyst Charles Pitman raised the price target on H Lundbeck A/S (HLUNB:DC) (OTC: HLUYY) to DKK48.00  (from DKK45.00) while maintaining a Equalweight rating.</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Analyst+PT+Change/H+Lundbeck+AS+%28HLUNB%3ADC%29+%28HLUYY%29+PT+Raised+to+DKK48+at+Barclays/26781242.html</guid>
   <pubDate>Fri, 17 Jul 2026 04:49:05 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">HLUYY</category>
   	  </item>
  <item>
   <title>H Lundbeck A/S (HLUNB:DC) (HLUYY) PT Raised to DKK48 at Barclays</title>
   <link>http://www.streetinsider.com/Intl+Ratings/H+Lundbeck+AS+%28HLUNB%3ADC%29+%28HLUYY%29+PT+Raised+to+DKK48+at+Barclays/26781242.html</link>
   <description>Barclays analyst Charles Pitman raised the price target on H Lundbeck A/S (HLUNB:DC) (OTC: HLUYY) to DKK48.00  (from DKK45.00) while maintaining a Equalweight rating.</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Intl+Ratings/H+Lundbeck+AS+%28HLUNB%3ADC%29+%28HLUYY%29+PT+Raised+to+DKK48+at+Barclays/26781242.html</guid>
   <pubDate>Fri, 17 Jul 2026 04:49:05 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">HLUYY</category>
   	  </item>
 </channel>
</rss>
